Robin Kate Kelley

Robin Kate Kelley contributed to the KEYNOTE-937 trial examining adjuvant pembrolizumab in resected HCC and leads clinical trials in hepatobiliary cancers including adjuvant strategies for HCC and cholangiocarcinoma. Her research encompasses FGFR-targeted therapy in intrahepatic cholangiocarcinoma and immunotherapy combinations in HCC. She leads a comprehensive hepatobiliary oncology program at UCSF and contributes to NCCN guidelines for HCC and biliary tract cancers. Kelley is recognized for translating molecular insights into adjuvant and systemic clinical trials for liver cancer.